What Is Synthetic Lethality?
Learn about synthetic lethality and approved drugs that use this approach to treat cancer.
Learn about synthetic lethality and approved drugs that use this approach to treat cancer.
An exciting area in drug development, immunotherapy is being increasingly utilized by patients with different cancer types. These treatments...
The number of anticancer immunotherapeutics approved by the U.S. Food and Drug Administration (FDA) is rising rapidly. In fact,...
Guest Post by William G. Nelson, MD, PhD Editor-in-Chief, Cancer Today
Guest Post by William G. Nelson, MD, PhD Editor-in-Chief, Cancer Today
A short time after Mallika Lala, PhD, finished her presentation titled “Pembrolizumab 400 mg Q6W dosing: First clinical outcomes...
A study presented at the AACR Annual Meeting 2018 discussed preliminary data on an off-the-shelf, T-cell receptor (TCR)-less, dual-targeted...
Prostate cancer is one of the most common cancers diagnosed in the United States. About one-third of men diagnosed...
Editor’s Note: Several prominent American Association for Cancer Research (AACR) leaders have shared their reactions to President Obama’s Jan....
An emerging hallmark of cancer cells is their ability to hide from the body’s immune system. The human immune...
Party With a Purpose will honor Penn surgeon Jeffrey Drebin and will donate funds from its gala to the...
In 2019, Michael D. Story, PhD, vice chair of the Department of Radiation Oncology and chief of the Division of Molecular Radiation Biology at UT Southwestern Medical Center, was one of...
Epithelial ovarian cancer is by far the most common ovarian cancer subtype, accounting for 90 percent of ovarian cancers. The...
Since COVID-19 first began its siege on the world, much of our scientific knowledge about the disease—and its source...
As the coronavirus pandemic took root in the United States, many hospitals and cancer centers temporarily suspended treatments and...
Cancer treatments have been, and continue to be in most cases, based on the organ site where the tumor...
In the early 1990s, Gregg Semenza, MD, PhD, was a postdoctoral researcher studying the cellular response to reduced oxygen levels, a...
When the COVID-19 pandemic forced much of the world to shut down, and many days seemed bleak, it was...
“The immuno-oncology revolution is now about 15 years into clinical reality,” said Carl June, MD, FAACR, director of the...
In recent years, the American Association for Cancer Research (AACR) has expanded its efforts to catalyze advances in cancer...
Guest Post by Sammantha McDonald Past participant in the AACR’s Scientist↔Survivor Program (SSP)
One of the most effective ways a person can lower his or her risk of developing cancer is by...
In just over a month, the Georgia World Congress Center in Atlanta will host the American Association for Cancer...
This month is Breast Cancer Awareness Month, a type of cancer against which we have made much progress. However,...
For the past five years, cohorts of talented young researchers from around the world have participated in the AACR...
AACRoC in Brazil let young investigators learn from cancer research experts during programs in São Paulo and Ribeirão Preto.
February 11 marks the International Day of Women and Girls in Science, a United Nations initiative to encourage full...
When the hottest minds in cancer genomics meet the hottest minds in computational and systems biology, you can rest...
Guest post by Roy S. Herbst, MD, PhD Yale Comprehensive Cancer Center
Surrounding a tumor is a vast network of blood vessels, immune cells, proteins, and even bacteria, all of which...